Combined follow up
In scenarios where both HCT and cellular therapy forms are being completed, there are duplicate questions across the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450) forms and the Cellular Therapy Essential Data Follow-Up (4100) form. To reduce the reporting burden, duplicate questions, including GVHD, on the Cellular Therapy forms are disabled and will be answered on the Post-HSCT Data (2100) or Post-Transplant Essential Data (2450) form.

Graft versus Host Disease (GVHD) is an immunological phenomenon resulting from the reaction of donor immune cells against major or minor histocompatibility antigens of the recipient. GVHD is primarily caused by donor-derived T-cells. Very rarely, GVHD may occur due to autologous reactivity (autologous GVHD), third party transfusions, or with identical twin transplantation.

Factors influencing the severity of GVHD are related to three main categories: 1) donor or graft, 2) recipient, and 3) treatment. The most influential donor/graft factor is the degree of genetic disparity between the donor and the recipient (HLA match), but other risk factors include female donor to male recipient, donor parity, older donors, and T-cell dose. The occurrence of acute GVHD becomes a risk factor for the development of chronic GVHD. Recipient age and prior infections are also factors.

In the past, GVHD was classified as acute or chronic based on its time to diagnosis following transplant, and other clinical and histological (biopsy or post-mortem) features. Today, there has been increased recognition that acute and chronic GVHD are not dependent upon time since infusion, so determination of acute or chronic should rest on clinical and histologic features. However, organ staging, and overall grade should only be calculated from the clinical picture, not histology. Acute GVHD usually begins between 10 and 40 days after HCT but can appear earlier or later. The organs most commonly affected by acute GVHD are the skin, gut, or liver. Other sites, such as the lung, may be involved.

Question 60: Did acute GVHD develop since the date of last report?

Questions 60 and 62 on the Cellular Therapy Essential Data Follow-Up Form are meant to capture whether the recipient had active symptoms of acute GVHD during the reporting period. If the recipient had active acute GVHD during the reporting period, either question 60 or question 62 must be answered Yes unless there has been a prior / concurrent diagnosis of chronic GVHD (see note above question 60). There will not be a situation where Yes is reported for both question 60 and question 62. If question 60 is answered yes and a diagnosis date has been reported in question 61, question 62 will be disabled in FormsNet3SM. Centers should report Yes for question 60 to indicate the recipient developed acute GVHD in the following scenarios:

  • Acute GVHD is diagnosed for the first time during the reporting period
  • An acute GVHD flare is diagnosed during the current reporting period and all of the following conditions are met:
    • The recipient’s prior acute GVHD symptoms did not persist from the prior reporting period into the beginning of current reporting period.
    • The flare is diagnosed after at least 30 days without any active acute GVHD symptoms.
    • The recipient was not diagnosed with chronic GVHD on or before the date of the flare (see note above question 60).

If the recipient does have active acute GVHD during the reporting period, but does not match either of the scenarios above, the center will likely need to report No for question 60 and Yes for question 62. Question 62 is intended to capture acute GVHD which has continued from a prior reporting period. This includes any flares which do not meet the above conditions. The intent of classifying GVHD episodes as newly developed or persistent is to avoid having centers re-report diagnosis information which has been captured on a prior form. Refer to the Acute GVHD diagnosis scenarios below to see examples of how to answer questions 60 and 62.

Report No for questions 60 and 62 if the recipient had no active acute GVHD symptoms during the reporting period OR all acute GVHD signs / symptoms during the reporting period occurred after a diagnosis of chronic GVHD (see note above question 60).

Indicate Unknown if there is no information about the recipient’s GVHD status for the reporting period. This option should be used sparingly and only when no judgment can be made about the presence or absence of GVHD in the reporting period.

Acute GVHD Diagnosis Scenarios:

A. A recipient receives a cellular therapy infusion of an allogeneic product on 1/1/2015 and develops acute GVHD which is clinically diagnosed on 2/1/2015. At least one of their symptoms, attributed to acute GVHD, persists beyond the 100 day date of contact which is 4/5/2015. Treatment continues and symptoms completely resolve on 5/1/2015. Immunosuppression is tapered until a flare of acute GVHD is diagnosed on 5/25/2015. Immunosuppression is given and symptoms quickly resolve with no active acute GVHD
beginning 6/10/2015. The six month date of contact is 6/20/2015. Another flare of acute GVHD is clinically diagnosed on 8/15/2015.

100 Day Post-TED Form:
Question 60: Report “yes” to indicate a new clinical diagnosis of acute GVHD. Question 61: Report the initial date of diagnosis (2/1/2015).
Question 62: Leave blank. This question will be skipped whenever a diagnosis date has been entered in question 61.
Questions 63-69: Answer these questions based on the assessments performed at the time of diagnosis (2/ 1/2015).

Six Month Post-TED Form:
Question 60: Report “no” to indicate acute GVHD persists from a previous report. Note, the flare of acute GVHD was < 30 days from symptoms resolution so it doesn’t count as a new reportable episode.
Question 61: Leave blank. This question will be skipped whenever question 60 is answered “no.”
Question 62: Report “yes” to indicate GVHD persists from a previous report.
Questions 63-69: Leave blank. Answering “yes” for question 62 prevents the center from re-reporting diagnosis information already captured on the 100 day form.

One Year Post-Infusion Data Form:
Question 60: Report “yes” to indicate a flare of acute GVHD occurred at least 30 days after resolving during a prior reporting period.
Question 61: Report the diagnosis date of the flare occurring during the reporting period (8/15/2015).
Question 62: Leave blank. This question will be skipped whenever a diagnosis date has been entered in question 61.
Questions 63-69: Answer these questions based on the assessments performed at the time of diagnosis of the flare of acute GVHD (8/15/2015).

B. A recipient receives a cellular therapy infusion of an allogeneic product on 1/1/2015 and develops acute skin GVHD on 2/1/2015 and then chronic eye GVHD on 3/1/2015. Both acute and chronic symptoms resolve by the 100 day date of contact (4/5/2015). While tapering their immunosuppression, the recipient has a flare of their acute skin GVHD on 5/30/2015. Treatment continues and symptoms completely resolve by the six month date of contact (6/20/2015).

100 Day Post-Infusion Data Form:
Question 60: Report “yes” to indicate a new clinical diagnosis of acute GVHD.
Question 61: Report the initial date of diagnosis (2/1/2015).
Question 62: Leave blank. This question will be skipped whenever a diagnosis date has been entered in question 61.
Questions 63-69: Answer these questions based on the assessments performed at the time of diagnosis (2/ 1/2015).

Six Month Post-Infusion Data Form:
Question 60: Report “no” to indicate acute GVHD did not develop during the reporting period.
Question 61: Leave blank. This question will be skipped whenever question 60 is answered “no.”
Question 62: Report “no” to indicate acute GVHD did not persist from a previous report.

If chronic GVHD has been diagnosed in a prior reporting period, report “no” for questions 60 and 62. Any new or persistent acute GVHD symptoms occurring after the onset of chronic GVHD must be reported in the chronic GVHD section of the form. Do not include any signs, symptoms, or treatment occurring on or after the onset of chronic GVHD when completing the acute GVHD section. This instruction has been provided in the note above question 60.

Question 61: Date of acute GVHD diagnosis:

Report the date of clinical diagnosis of acute GVHD. The clinical diagnosis date may not necessarily be the date the symptoms began (example: the recipient developed a rash one week prior to the physician clinically diagnosing acute skin GVHD). If the clinical diagnosis is documented, but the diagnosis date is unclear, obtain documentation from the primary physician confirming the clinical diagnosis date.

If the recipient developed more than one episode of acute GVHD in the same reporting period, report the date of onset of the first episode of acute GVHD.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

Question 62: Did acute GVHD persist since the date of last report?

Question 62 will only be enabled in FormsNet3 if the center has reported No for question 60 and, therefore, has not reported a date of diagnosis in question 61. If prompted to answer question 62, report Yes if acute GVHD was diagnosed in a prior reporting period and any of the following conditions are met:

  • The recipient’s acute GVHD symptoms have been active since diagnosis and continue to be active during the current reporting period (i.e., no period of resolution or quiescence since diagnosis).
  • The recipient’s acute GVHD symptoms had resolved before the first day of the current reporting period, but a flare occurred within 30 days of symptom resolution / quiescence.
  • The recipient was not diagnosed with chronic GVHD on or before the date of the flare (see note above question 60).

Report No for questions 60 and 62 if the recipient had no active acute GVHD symptoms during the reporting period or all acute GVHD signs / symptoms during the reporting period occurred after a diagnosis of chronic GVHD (see note above question 60).

Indicate Unknown if there is no information about the recipient’s GVHD status for the reporting period. This option should be used sparingly and only when no judgment can be made about the presence or absence of GVHD in the reporting period.

Question 63: Overall grade of acute GVHD at diagnosis:

Indicate the overall grade of acute GVHD at the time of diagnosis. The acute GVHD grading scale is based on clinical evidence (physician observation), not histology. Pathology reports sometimes list a histologic grade of GVHD. Do not report the histologic grade. GVHD scoring and grading is based on clinical severity, not histologic severity. Biopsy of affected organs allows for more precise diagnosis as to the presence or absence of GVHD. However, overall grading remains clinical and is based on the criteria published by Przepiorka et al., Bone Marrow Transplant 1995; 15(6):825-8, see the GVHD Grading and Staging table below.

If acute GVHD was present, but the grade at diagnosis was not documented and it cannot be determined from the grading and staging table, report Not applicable.

Examples may include:

  • Only elevated liver function tests without increased bilirubin
  • Any other organ involvement without skin, liver, or gut symptoms attributable to GVHD
  • Lower intestinal tract involvement where the stage cannot be determined in select scenarios (see lower intestinal tract involvement description below)

Question 64-69: List the stage for each organ at diagnosis of acute GVHD:

Skin: Select the stage that reflects the body surface area involved with a maculopapular rash attributed to acute GVHD at the time of acute GVHD diagnosis or flare in the reporting period. See the Percent Body Surfaces table below to determine the percent of body surface area involved with a rash. Do not report ongoing rash not attributed to acute GVHD at the time of acute GVHD diagnosis or flare.

Percent Body Surfaces

Table showing percent of body surfaces that can be affected by GVHD.

Lower intestinal tract (use mL/day for adult recipients and mL/m2/day for pediatric recipients): Select the stage that reflects the volume of diarrhea attributed to acute GVHD at the time of acute GVHD diagnosis or flare in the reporting period. Use mL/day for adult recipients and mL/m2/day for pediatric recipients. Input and output records may be useful in determining the volume of diarrhea. Do not report ongoing diarrhea not attributed to acute GVHD at the time of acute GVHD diagnosis or flare.

If diarrhea is attributed to acute GVHD during the reporting period, but the volume of stool output is not documented, report “stage 0” for lower intestinal tract involvement. In this case, report “not applicable” for the overall grade unless stage 4 acute skin GVHD, stage 4 acute liver GVHD, or an extreme decrease in performance status was also documented at the time point being reported (at diagnosis or maximum grade during the reporting period). Report an overall grade of IV if stage 4 acute skin GVHD, stage 4 acute liver GVHD, or an extreme decrease in performance status is documented at the time point being reported (see GVHD Staging and Grading Table). Report overall grade III if stage 2-3 liver involvement is documented at the time point being reported and there is no evidence of grade IV GVHD.

Upper intestinal tract: Select the stage that reflects the presence of persistent nausea or vomiting attributed to acute GVHD at the time of acute GVHD diagnosis or flare in the reporting period. Do not report ongoing nausea or vomiting not attributed to acute GVHD at the time of acute GVHD diagnosis or flare.

Liver: Select the stage that reflects the bilirubin level attributed to acute GVHD at the time of acute GVHD diagnosis or flare in the reporting period. Do not report ongoing hyperbilirubinemia not attributed to acute GVHD at the time of acute GVHD diagnosis or flare.

For recipients who have a normal bilirubin level with elevated transaminase levels attributed to acute GVHD, report this in questions 65-66 “Other site(s) involved with acute GVHD”.

Other site(s) involved with acute GVHD: Indicate whether acute GVHD affected an organ other than skin, upper GI, lower GI, or liver manifesting with hyperbilirubinemia. This includes transaminitis attributed to acute GVHD. Report only other organ involvement at the time of acute GVHD diagnosis or flare in the reporting period. Do not report symptoms ongoing but not attributed to acute GVHD at the time of acute GVHD diagnosis or flare. Specify the other organ system involvement in question 69. If reporting transaminitis under Other site, write in “transaminitis” rather than “liver” when specifying the site. This will prevent queries regarding incorrectly reporting liver GVHD (with bilirubin elevation) under “other site.”

Question 70: Maximum Overall Grade of Acute GVHD:

Indicate the overall maximum grade of acute GVHD since the date of the last report. Grading is based on clinical evidence (physician observation), not histology. Pathology reports sometimes list a histologic grade of GVHD. Do not report the histologic grade. GVHD scoring and grading is based on clinical severity, not histologic severity. Biopsy of affected organs allows for more precise diagnosis as to the presence or absence of GVHD. However, overall grading remains clinical and is based on the criteria published by Przepiorka et al., Bone Marrow Transplant 1995; 15(6):825-8; see the GVHD Grading and Staging table above.

If chronic GVHD was diagnosed during the reporting period, report the maximum severity of acute GVHD prior to the onset of chronic GVHD. See question 60 for further instructions. Acute GVHD grading scenario D below has been provided for further clarification.

Report the recipient’s maximum acute GVHD grade in the reporting period; this may differ from the grade at diagnosis or may be the same. If acute GVHD was present, but the maximum grade was not documented and it cannot be determined from the grading and staging table, report Not applicable.

Examples may include:

  • Only elevated liver function tests without increased bilirubin
  • Any other organ involvement without skin, liver, or gut symptoms attributable to GVHD
  • Lower intestinal tract involvement where the stage cannot be determined in select scenarios (see lower intestinal tract involvement description above)

Acute GVHD Grading Scenarios:

A. A recipient developed stage 2 skin involvement and elevated liver function tests (LFTs) attributed to acute GVHD; however, there was no total bilirubin manifestation. In this case, overall maximum grade I acute GVHD should be reported since the staging / grading can be determined using the GVHD Grading and Staging table above.

B. A recipient developed acute liver GVHD with elevated LFTs (i.e., transaminases) with no total bilirubin manifestation. The progress notes indicate stage 1 (grade II overall) acute GVHD of the liver. In this case,
the clinical manifestations do not fit the criteria used in the GVHD Grading and Staging table above; “not applicable” would be the best option to report.

C. A recipient developed stage 2 skin involvement, which showed improvement in response to topical steroids. However, the recipient then developed hyperbilirubinemia attributed to stage 1 liver involvement; the skin involvement at that time was stage 1. In this case, grade II would be reported (assuming this was the extent of the recipient’s acute GVHD in the reporting period).

D. A recipient developed stage 2 skin involvement which resolved in response to topical steroids. Later in the reporting period, the recipient was diagnosed with mild chronic eye GVHD. Shortly thereafter, they were diagnosed with a stage 3 flare of acute skin GVHD. In this case, grade I would be reported. Do not consider any new or persistent acute GVHD symptoms occurring after the onset of chronic GVHD when completing the acute GVHD section of the form.

Question 71: Date maximum overall grade of acute GVHD

Report the date (YYYY-MM-DD) of maximum acute GVHD involvement, based on clinical grade. If the recipient had multiple instances in which their GVHD reached the same maximum grade, report the earliest date. If Not applicable was reported for question 70, question 71 must be left blank.

Question 72: Did chronic GVHD develop since the date of last report?

Indicate whether a new clinical diagnosis of chronic GVHD was documented during the reporting period. If chronic GVHD was diagnosed during the reporting period, report Yes and continue with question 73.

If the recipient had a flare of chronic GVHD occurring after at least a 30 day period of symptom quiescence, report Yes and continue with question 73. Report No if symptoms resolve or become quiescent prior to the date of last report and then flare within 30 days. This should be reported as persistent chronic GVHD which is captured in question 74.

Report No if chronic GVHD was not clinically diagnosed – initially or as a flare – in the reporting period; this includes instances where chronic GVHD persists from a prior reporting period without flare in the current reporting period.

Indicate Unknown if there is no information about the recipient’s GVHD status for the reporting period. This option should be used sparingly and only when no judgment can be made about the presence or absence of GVHD in the reporting period.

Question 73: Date of chronic GVHD diagnosis:

Report the date (YYYY-MM-DD) of clinical diagnosis of chronic GVHD. The clinical diagnosis date may not necessarily be the date the symptoms began (example: the recipient developed shortness of breath one month prior to the clinical diagnosis of pulmonary chronic GVHD). If the clinical diagnosis is documented, but the diagnosis date is unclear, obtain documentation from the primary physician confirming the clinical diagnosis date.

If the recipient developed more than one episode of chronic GVHD in the same reporting period, report the date of onset of the first episode of chronic GVHD.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

Question 74: Did chronic GVHD persist since the date of last report?

Question 74 will only be enabled in FormsNet3 if the center has reported No for question 72 and, therefore, has not reported a date of diagnosis in question 73. Indicate whether chronic GVHD was clinically diagnosed during a previous reporting period and persisted, with active symptoms, into the present reporting period. Do not report quiescent or inactive chronic GVHD, or a prior history of GVHD. If Yes, continue with question 75; See question 72 for instructions on reporting a chronic GVHD flare.

If the recipient has no active symptoms during the reporting period, report No and continue with question 78.

Indicate Unknown if there is no information about the recipient’s GVHD status for the reporting period. This option should be used sparingly and only when no judgment can be made about the presence or absence of GVHD in the reporting period.

Question 75: Maximum grade of Chronic GVHD (according to best clinical judgement):

Report the maximum chronic GVHD involvement, based on clinical grade, as documented by the recipient’s primary care provider. The intent of this question is to capture the maximum grade based on the best clinical judgment. If the maximum clinical grade is not documented, request documentation from the recipient’s primary care provider.

Indicate Unknown if there is no information about the recipient’s GVHD status for the reporting period. This option should be used sparingly and only when no judgment can be made about the presence or absence of GVHD in the reporting period.

Question 76: Specify if chronic GVHD was limited or extensive:

The grading system for chronic GVHD is divided into two categories: limited and extensive. Definitions are based on Sullivan KM, Blood 1981; 57:267.

Report Limited if chronic GVHD includes only localized skin involvement and/or liver dysfunction. Report Extensive if any of the following symptoms are attributed to chronic GVHD:

Generalized skin involvement and/or liver dysfunction

  • Liver histology showing chronic aggressive hepatitis, bridging necrosis, or cirrhosis
  • Involvement of the eye: Schirmer’s test with <5 mm wetting**, or
  • Involvement of the salivary glands or oral mucosa, or
  • Involvement of any other target organ

Note: Schimer’s test is required if eye involvement is the only symptom of chronic GVHD. If there are other symptoms of chronic GVHD such as lichen sclerosis of the mouth and skin involvement in addition to the eye symptoms, the Schirmer’s test is not required.

Question 77: Date of maximum grade of chronic GVHD:

Report the date (YYYY-MM-DD) of maximum chronic GVHD involvement, based on clinical grade. If the recipient had multiple instances in which their GVHD reached the same maximum grade, report the earliest date.

If the exact date is unknown, please view General Instructions, General Guidelines for Completing Forms for more information on reporting partial and unknown dates.

Question 78: Is the recipient still taking systemic steroids? (Do not report steroids for adrenal insufficiency or a steroid taper of ≤10 mg/day for adults, <0.1 mg/kg/day for children)

Indicate whether the recipient is still taking immunosuppressive agents to treat or prevent GVHD on the date of contact. Refer to the guidelines included in the question text if the recipient is taking low dose steroids or steroids for adrenal insufficiency.

Indicate Not applicable in any of the following scenarios:

  • The recipient has never received systemic steroids (> 10 mg / day for adults or ≥ 0.1 mg / kg / day for children) to treat or prevent GVHD.
  • The recipient stopped taking systemic steroids (> 10 mg / day for adults or ≥ 0.1 mg / kg / day for children) to treat or prevent GVHD in a previous reporting period and did not restart systemic steroids (> 10 mg / day for adults or ≥ 0.1 mg / kg / day for children) during the current reporting period.

Indicate Unknown if there is no information to determine if the recipient is still taking systemic steroids. This option should be used sparingly and only when no judgment can be made about the recipient still receiving treatment for GVHD on the date of contact. If the recipient has died prior to the discontinuation of systemic steroids used to treat or prevent acute and / or chronic GVHD, select Yes.

Question 79: Is the recipient still taking (non-steroid) immunosuppressive agents (including PUVA) for GVHD?

Indicate whether the recipient is still taking non-steroidal immunosuppressive agents (including PUVA) to treat or prevent acute and / or chronic GVHD on the date of contact. Descriptions of many immunosuppressive agents are included below.

If the recipient did not receive non-steroidal immunosuppressive agents to treat or prevent acute and / or chronic GVHD during the reporting period, report Not applicable. Indicate Not applicable in any of the following scenarios:

  • The recipient has never received non-steroidal immunosuppressive agents (including PUVA) to treat or prevent GVHD.
  • The recipient stopped taking non-steroidal immunosuppressive agents (including PUVA) to treat or prevent GVHD in a previous reporting period and did not restart non-steroidal immunosuppressive agents (including PUVA) during the current reporting period.

Indicate Unknown if there is no information to determine if the recipient is still taking non-steroidal immunosuppressive agents. This option should be used sparingly and only when no judgment can be made about the recipient still receiving treatment for GVHD in the reporting period.

Examples of Immunosuppressive Agents:

Aldesleukin (Proleukin): Increases production of several white blood cells including regulatory T-cells. This drug is also known as interleukin-2.

ALG (Anti-Lymphocyte Globulin), ALS (Anti-Lymphocyte Serum), ATG (Anti-Thymocyte Globulin) ATS (Anti-Thymocyte Serum): Serum or gamma globulin preparations containing polyclonal immunoglobulins directed against lymphocytes. These drugs are usually prepared from animals immunized against human lymphocytes. Also report the animal source. If “other” is selected, specify the source.

Azathioprine (Imuran): Azathioprine inhibits purine synthesis. Usually it is used at low doses in combination with other treatments.

Bortezomib (Velcade): A proteasome inhibitor.

Cyclosporine (CSA, Neoral, Sandimmune): Calcineurin inhibitor which decreases cytokine production by T-cells. Usually given for ≥ 3 months.

Cyclophosphamide (Cytoxan): Given in high doses near the date of infusion as single agent prophylaxis.

Extra-corporeal photopheresis (ECP): The recipient’s blood is removed from the body, exposes to psoralen and ultraviolet light, and re-infused.

FK 506 (Tacrolimus, Prograf): Inhibits the production of interleukin-2 by T-cells.

Hydroxychloroquine (Plaquenil): Hydroxychloroquine inhibits transcription of DNA to RNA and is commonly used as an anti-malarial drug.

Interleukin Inhibitor: Interleukin inhibitors suppress production of white blood cells and are grouped according to their target. Examples of IL-2 inhibitors include daclizumab (Zynbryta) and basiliximab (Simulect). Examples of IL-6 inhibitors include tocilizumab (Actemra) and siltuximab (Sylvant).

In vivo monoclonal antibody: Antibody preparations that are infused in the recipient following HCT. Specify the antibody used as: anti CD25 (Zenapax, Daclizumab, AntiTAC), alemtuzumab (Campath), entanercept (Enbrel), infliximab (Remicade), and / or rituximab (Rituxan).

In vivo immunotoxin: Antibody preparations linked to a toxin that is infused in the recipient following HCT. Specify the immunotoxin.

Janus Kinase 2 Inhibitors: Suppress function of T-effector cells. Examples: ruxoloitinib (Jakafi, Jakavi) and tofacitinib (Xeljanz, Jakvinus).

Methotrexate (MTX) (Amethopterin): Inhibits the metabolism of folic acid. It is most often used with cyclosporine and is usually for a short duration of time.

Mycophenolate mofetil (MMF) (CellCept, Myfortic): Inhibits the de novo pathway used for lymphocyte proliferation and activation.

Pentostatin (Nipent): Inhibits adenosine deaminase, which blocks DNA (and some RNA) synthesis.

Sirolimus (Rapamycin, Rapamune): Inhibits the response to interleukin-2, blocking the activation of T- cells.

Tyrosine Kinase Inhibitor (TKI): Suppress function of tyrosine kinases thereby downregulating the function of many other cellular proteins / processes including fibrosis and inflammation. Examples: imatinib (Gleevec, Glivec), nilotinib (Tasigna), and dasatinib (Sprycel).

UV Therapy: UVA or UVB radiation administered to affected areas of the skin in order to suppress proliferation of cells responsible for GVHD.

PUVA (Psoralen and UVA): Psoralen is applied or taken orally to sensitize the skin, and then the skin is exposed to UVA radiation.

UVB: Broadband- or Narrowband-UVB radiation is applied to the affected areas of the skin.

Section Updates:

Question Number Date of Change Add/Remove/Modify Description Reasoning (If applicable)
. . . . .
Last modified: Jan 22, 2021

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.